dr. balar discusses keynote-057 study in nmibc
Published 5 years ago • 75 plays • Length 1:07Download video MP4
Download video MP3
Similar videos
-
1:37
dr. balar on next steps of the keynote-057 trial in nmibc
-
0:57
dr. balar on rationale for keynote-057 in nmibc
-
0:45
copy of dr. balar on next steps of the keynote-057 trial in nmibc
-
3:16
keynote-057 update: pembrolizumab for high-risk nmibc patients
-
6:17
interview with dr. balar
-
2:01
keynote-057 cohort b: pembrolizumab for bcg-unresponsive, high-risk nmibc
-
1:09
dr. balar on current and future standards of care in kidney cancer treatment
-
1:32
dr. balar discusses study of immunotherapy combination in bladder cancer
-
32:30
bladder cancer and immunotherapy with dr. terence friedlander
-
34:39
bladder cancer and immunotherapy with dr. arjun balar
-
1:03:30
world wide neuro | sussex vision series - 24/07/2023 - prof. karthik shekhar
-
2:22
keynote-057: extended follow-up of pembrolizumab in bladder cancer
-
1:33
dr. balar on results of durvalumab plus tremelimumab in bladder cancer
-
1:52
dr. balar on immunotherapy treatment in bladder cancer
-
1:09
dr. balar on improved outlook in metastatic bladder cancer
-
0:48
dr. balar on the future of immunotherapy in bladder cancer
-
0:54
dr. balar on biomarkers of immunotherapy response in bladder cancer
-
1:17
dr. balar discusses bevacizumab in bladder cancer
-
1:07
dr. balar on impact of durvalumab plus tremelimumab in bladder cancer
-
0:51
dr. balar on the approval of pembrolizumab for bladder cancer
-
1:57
dr. balar on mature clinical results of keynote-052 in urothelial cancer
-
1:57
dr. balar on remaining questions with immunotherapy in bladder cancer